Short answer
Nuvectis Pharma, Inc. (NVCT) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$7M
- −79.7% YoY · −17.8% QoQ
- EPS (diluted)
- −$0.45
- −87.5% YoY · −55.2% QoQ
Source: XBRL data from the Nuvectis Pharma, Inc. (NVCT) Q3 2025 10-Q on SEC EDGAR. USD.
Nuvectis Pharma, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY; net loss $7.5M vs $4.2M
- Operating margin not applicable; operating loss $7.8M vs $4.4M
- NXP900 development: R&D expenses $5.8M, up 105% YoY
- Cash $35.4M at September 30; operating cash use $12.0M through nine months
- Outlook: expenses expected to increase; funding projected through at least next 12 months
Risk Factors
- Newly highlighted tariff risk, triggered by U.S. trade-policy uncertainty, potentially increasing imported laboratory and raw-material costs
- NXP800 ovarian-cancer program setback, following 17-patient Phase 1b data showing 2 partial responses and 3 stable diseases
- Regulatory risk from FDA funding disruptions or government shutdowns, potentially delaying product reviews and access to public-market capital
- Clinical-development risk, with NXP800 thrombocytopenia requiring intermittent dosing and further development in ovarian cancer discontinued
- Funding risk, with accumulated deficit of $92.4 million through September 30, 2025 and substantial additional capital required
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nuvectis Pharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.